Table 2.
Summary of intercellular mitochondrial transfer under pathological conditions
Donors | Recipients | Induction factor | Transferred cargoes | Route | Transfer outcomes | Ref. |
---|---|---|---|---|---|---|
CNS | ||||||
Astrocytes | Neurons | Ischemic damage | Healthy mitochondria | MVs (CD38) | Restoration of ATP levels and neuronal viability | 12 |
MMSCs | Neurons | Ischemic damage | Healthy mitochondria | TNTs | Recovery of respiration and neurological functions | 31 |
MMSCs | Astrocytes | Ischemic damage | Healthy mitochondria | TNTs (Miro1) | Restoration of bioenergetics and promotion of cell proliferation | 32 |
EPCs | Brain endothelial cells | OGD | Isolated mitochondria | Internalization |
Elevated levels of mitochondrial protein, mtDNA copy number, and intracellular ATP; restoration of endothelial tightness |
35 |
Astrocytes | Cerebrospinal fluid | Subarachnoid hemorrhage | Healthy mitochondria | Not verified | Brain recovery and good clinical outcomes | 36 |
PC12 cells Soleus cells |
Spinal cord-resident cells | SCI | Isolated mitochondria | Internalization | Maintenance of acute bioenergetics after SCI | 37 |
BM-MSCs | Motor neurons | OGD/SCI | Healthy mitochondria/isolated mitochondria | TNTs/gap junction | Improved bioenergetics profile and cell survival in post-OGD motor neurons; locomotor functional recovery after SCI | 38 |
MSCs | NSCs | Cisplatin | Healthy mitochondria | TNTs (Miro1) | Decrease of NSC death and restoration of mitochondrial membrane potential | 39 |
Astrocytes | Neurons | Cisplatin | Healthy mitochondria | Not verified | Increased neuronal survival and restored neuronal calcium dynamics | 40 |
HeLa cells | AD mice model | None | Isolated mitochondria | Intravenous injection | Amelioration of cognitive deficits, neuronal loss, and gliosis in Alzheimer’s disease mice | 41 |
Astrocytes | Astrocytes | α-Syn ingestion and accumulation | Healthy mitochondria | TNTs | Potential rescue of mitochondrial dysfunction in stressed α-syn-containing astrocytes | 43 |
Cardiovascular system | ||||||
Pectoralis major muscle cells | CMs | Ischemic damage | Isolated mitochondria | Internalization | Decreased heart infarct size of rabbits | 56 |
BM-MSCs | Cardiomyoblasts | Ischemic damage | Healthy mitochondria | TNTs | Rescue of cardioblasts from cell death | 57 |
MFs | CMs | Hypoxia/reoxygenation damage | Healthy mitochondria | TNTs | Rescue of CMs from apoptosis | 58 |
MSCs | CMs | LPS-induced stress | Healthy mitochondria | TNTs | Enhancement of cardiomyocyte function | 59 |
iPSC-MSCs | CMs | Anthracycline-induced cardiomyopathy | Healthy mitochondria | TNTs (TNFαip2, Miro1) | Rescue of CMs damage | 60 |
Respiratory system | ||||||
BMSCs | Alveolar epithelium cells | LPS-induced ALI | Healthy mitochondria | TNTs/MVs (Cx43) | Restoration of alveolar bioenergetics and elevation of the survival rate | 11 |
iPSC-MSCs | Bronchial epithelial cells (BEAS-2B) | CS-induced COPD | Healthy mitochondria | TNTs | Alleviation of CS-induced ATP depletion and lung damage | 61 |
MSCs | Lung epithelial cells | Rotenone-induced airway injury | Healthy mitochondria | TNTs (Miro1) | Decrease in apoptosis and lung injury repair | 69 |
iPSC-MSCs | Bronchial epithelial cells (BEAS-2B) | Ovalbumin- or CoCl2-induced mitochondrial dysfunction | Healthy mitochondria | TNTs (Cx43) | Alleviation of airway inflammation and cell apoptosis | 64 |
Musculoskeletal system | ||||||
BM-MSCs | Chondrocytes | Rotenone and oligomycin | Healthy mitochondria | Not verified | Not verified | 71 |
Osteocytes/MLO-Y4 cell lines | MLO-Y4 ρ° cells | EB-induced mtDNA deletion | Healthy mitochondria | Cell dendrites (ER–mitochondria contact) | ATP reproduction and alleviation of oxidative stress | 73 |
Other systems | ||||||
BM-MSCs | HUVECs | OGD and reoxygenation | Healthy mitochondria | TNTs | Aerobic respiration and protection of endothelial cells from apoptosis | 74 |
Healthy or MCA-treated human MSCs | Injured human MSCs | H2O2-induced oxidative stress | Healthy mitochondria | TNTs | Decrease of oxidative stress and increase of human MSC viability | 76 |
iPSC-MSCs | Corneal epithelial cells | Rotenone-induced mitochondrial dysfunction | Healthy mitochondria | TNTs (TNFαip2) | Protection against oxidative stress and repair of cornea | 75 |
WJ-MSCs | MERRF cybrid cells | mtDNA mutation | Healthy mitochondria | TNTs | Reduction of ROS and improvement of mitochondrial bioenergetics | 78 |
Tumorigenesis and tumor therapy resistance | ||||||
MSC skin fibroblasts | Lung adenocarcinoma A549 ρ° cells | EB-induced mtDNA deletion | Healthy mitochondria/mtDNA | Cytoplasmic extensions or broad cellular contact | Recovery of respiratory function and oxidative metabolism | 10 |
Cells in TME of the host mouse | Breast carcinoma 4T1 ρ° cells | EB-induced mtDNA deletion | mtDNA | Not verified | Recovery of respiratory capacity and tumor growth | 94 |
MSCs | Melanoma B16 ρ° cells | EB-induced mtDNA deletion | Healthy mitochondria | Not verified | Recovery of respiratory capacity and tumor growth | 95 |
hMSCs | Breast cancer MDA-MB-231 cells | None | Isolated mitochondria | Internalization | Increased proliferation and invasion capacities of cancer cells | 93 |
BM-MSCs | Osteosarcoma 143B ρ° cells | EB or rhodamine 6G-induced mitochondrial dysfunction | Healthy mitochondria | Not verified | Increase of intracellular ATP levels and restoration of mitochondrial function | 15 |
WJ-MSCs | Osteosarcoma 143B ρ° cells | EB-induced mtDNA deletion | Healthy mitochondria | TNTs | Restoration of bioenergetics and OXPHOS-dependent cellular growth | 77 |
Mesothelioma cells | Mesothelioma cells | Acidified hyperglycemic medium | Vesicles, mitochondria, proteins—bidirectional | TNTs | Cancer cell pathogenesis and invasion | 83 |
T24 bladder cancer cells | RT4 bladder cancer cells—noninvasive | None | Healthy mitochondria | TNTs | Increased invasiveness of RT4 cells | 98 |
BMSCs | Primary AML blasts | None | Healthy mitochondria | TNTs (NOX2, ROS) | Energy acquirements of the proliferating cancer cells | 89 |
Nonmalignant CD34+ cells | H2O2 | Not verified | Not clarified | |||
Highly glycolytic CAFs | Prostate cancer cells | None | Healthy mitochondria | TNTs | Increased OXPHOS metabolism and respiratory capacity of cancer cells | 97 |
Neighboring nonmalignant BMSCs | Multiple myeloma cells | None | Healthy mitochondria | TNTs (CD38, direct contact) | Increased ATP production and mitochondrial respiration of multiple myeloma cells | 84 |
Endothelial cells, MSCs | MCF7 breast cancer cells | Doxorubicin | Healthy mitochondria | TNTs | Chemoresistance | 92 |
Healthy PC12 cells | Pheochromocytoma-derived PC12 cells | UV radiation | Healthy mitochondria | TNTs | Rescue of apoptotic P12 cells | 87 |
Astrocytoma cells | Astrocytoma cells | Radiation treatment | Mitochondria, Calcium | Tumor microtubules (Cx43) | Formation of a self-repairing and radio-resistant network | 85 |
U87 glioblastoma cells | Adjacent U87 glioblastoma cells | Etoposide | Mitochondria | TNTs | Perinuclear concentration and rearrangement of mitochondria | 86 |
Bone marrow-derived MS-5 cell line | AML cells | Cytarabine | Healthy mitochondria | Endocytosis | Increase of ATP production and survival capacity of AML cells following chemotherapy | 88 |
Chemoresistant ovarian cancer cells | Chemoresistant or chemosensitive ovarian cancer cells | Hypoxia | Mitochondria | TNTs (mTOR pathway) | Synchronization of cancer cells against drug therapy | 96 |
Immunoregulation | ||||||
BM-MSCs | Monocyte-derived macrophages | LPS-induced ARDS | Healthy mitochondria | TNTs | Enhance the phagocytic effect of macrophages | 62 |
BM-MSCs | Monocyte-derived macrophages | Escherichia coli infection | Healthy mitochondria | TNTs | Enhance the oxidative phosphorylation and phagocytosis of macrophages | 104 |
BM-MSCs | Macrophages | LPS-induced ARDS | Healthy mitochondria | MVs | Promote an anti-inflammatory and highly phagocytic phenotype of macrophagy and ameliorate lung injury | 63 |
BM-MSCs | Th17 cells | IL-2 | Healthy mitochondria | Cell contact-dependent manner | Increased oxygen consumption and reduced production of pro-inflammatary cytokines; generation of T-regulatory cells | 105 |
MSCs | PBMCs | None | Healthy mitochondria | Not verified | T cell activation and T-regulatory (Treg) cell differentiation; suppressive effect of inflammatory response | 106 |
CD3+ T cells | Isolated mitochondria | Internalization | ||||
Intercellular degradation | ||||||
Retinal ganglion cells | Adjacent astrocytes | Rotenone | Damaged mitochondria | MVs | Donors: mitophagy for transcellular degradation and self-protection | 21 |
BM-MSCs | Macrophages | Oxidative stress to MSCs | Depolarized mitochondria | MVs |
Donors: Mitophagy of MSCs for self-protection Recipients: enhancement of macrophage energetics |
107 |
T-ALL cells | BM-MSCs | Ara-C- or MTX-induced intracellular oxidative stress | Damaged mitochondria | TNTs | Donors: mitophagy for reduction of intracellular ROS and enhancement of chemoresistant capacity | 91 |
BM-MSCs | T-ALL cells | Ara-C- or MTX-induced intracellular oxidative stress | Healthy mitochondria | TNTs | Recipients: chemoresistance | 91 |
Stressed CMs or HUVECs | MSCs | H2O2-induced oxidative stress | Damaged mitochondria | TNTs (ROS) | Donors: transmitophagy of stressed cells | 113 |
MSCs | Stressed CMs or HUVECs | H2O2-induced oxidative stress | Healthy mitochondria | TNTs (HO-1) | Recipients: survival of stressed cells | 113 |